BLOG

Japan’s Regenerative Medicine Laws: A Safety Guide for Patients

Published 2026.09.18 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

The field of regenerative medicine, particularly stem cell therapy, is attracting global attention as a promising approach for addressing various health concerns. Japan has emerged as a key destination for patients seeking these advanced treatments, not only for its technological innovation but also for its unique and structured regulatory environment. For international patients, understanding this legal framework is a critical step in making an informed decision.

This article explains Japan’s distinctive approach to overseeing regenerative medicine, focusing on the “Act on the Safety of Regenerative Medicine.” We will explore how this system works, what it means for treatments like Adipose-Derived Stem Cell Therapy, and what patients should know before considering treatment in Japan.

Understanding Japan’s Act on the Safety of Regenerative Medicine

In 2014, Japan implemented two key laws to govern and promote the field of regenerative medicine. One is the PMD Act (Pharmaceuticals and Medical Devices Act), which created a pathway for fast-track approval of regenerative medicine products. The other, and the focus for most clinical treatments provided at institutions like ours, is the Act on the Safety of Regenerative Medicine (ASRM).

The ASRM was established to ensure the safety of patients and to regulate the provision of regenerative therapies by medical institutions. Unlike a drug approval law that certifies a specific product for mass production and sale, the ASRM governs the process of providing treatment on a case-by-case or institutional basis. Under this act, medical clinics and hospitals must submit a detailed treatment plan to a certified committee for review. If approved, the plan is then submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW). This system creates a clear framework of oversight, transparency, and accountability for medical providers.

Purpose: To ensure the safe and appropriate provision of regenerative medicine while fostering its development.
Mechanism: Requires medical institutions to submit detailed treatment plans for external review and government notification.
Scope: Covers treatments using processed cells, including autologous stem cell therapies (using the patient’s own cells).

How This Framework Supports Patient Safety

The ASRM provides a structured environment that prioritizes patient safety. For a treatment like Adipose-Derived Stem Cell Therapy, where a patient’s own fat tissue is collected and the stem cells within are cultured and administered, the law mandates strict protocols. The treatment plan submitted by a clinic must detail every step of the process, from patient selection criteria and informed consent procedures to cell collection, processing, and administration methods.

A crucial element of this safety framework is the requirement to use a licensed Cell Processing Center (CPC). These facilities are specifically designed and operated to handle cell culturing and expansion in a sterile environment, minimizing the risk of contamination. The ASRM ensures that the entire chain of custody, from patient to lab and back to the patient, is managed under high standards. This government oversight helps ensure that treatments are not performed in an unregulated manner, offering a level of assurance to both domestic and international patients.

Adipose-Derived Stem Cell Therapy in Japan

Adipose-Derived Stem Cell Therapy involves harvesting a small amount of a patient’s own fat, isolating the mesenchymal stem cells (MSCs), expanding their numbers in a CPC, and then administering them back into the body, typically via an intravenous (IV) infusion. These MSCs have been reported to have properties that may help modulate inflammation, support tissue repair, and balance immune system functions.

It is important to understand that this therapy is provided as a private medical service (not covered by national health insurance). While using a patient’s own cells (autologous) may lower the risk of rejection compared to donor cells, no medical procedure is without potential risks or side effects. The potential benefits and risks vary for each individual and must be carefully evaluated by a physician. This treatment should not be seen as a replacement for standard medical care for specific diseases but rather as a potential option to be discussed with a doctor.

What International Patients Should Consider

For international patients exploring regenerative medicine in Japan, the ASRM provides a valuable layer of security. It signifies that a clinic is operating within a government-recognized framework. However, this legal structure does not guarantee a specific therapeutic outcome. The decision to undergo treatment should be based on a comprehensive understanding of the procedure and a thorough consultation with a medical professional.

Here are some key points to confirm before proceeding:

Physician Consultation is Essential: A doctor must determine if you are a suitable candidate based on your health condition, medical history, and diagnostic tests. This is a critical first step to assess potential benefits versus risks.
Understand the Process: Inquire about the entire treatment flow, including fat collection, cell processing time, and the method of administration.
Clarify Costs and Duration: As a non-insured treatment, all costs are the patient’s responsibility. Ensure you have a clear understanding of the fees, the number of treatments that may be suggested, and the overall timeline.
Inquire about Legal Compliance: Ask if the treatment is provided under a plan accepted by the MHLW in accordance with the Act on the Safety of Regenerative Medicine.

Consulting with Our Team in Osaka

At Grand Green Osaka Umekita Clinic, we provide Adipose-Derived Stem Cell Therapy in full compliance with the Act on the Safety of Regenerative Medicine. Our process is built on a foundation of patient safety, thorough explanation, and personalized care. We believe the purpose of this therapy is not only to address current concerns but also to support long-term health and well-being.

If you are considering regenerative medicine and wish to understand your options, we encourage you to seek a professional medical opinion. Our clinic in Osaka offers consultations to help you learn more about the treatment in a clear and transparent manner. For more details on our approach to Adipose-Derived Stem Cell Therapy, including the process and safety management protocols, please visit our information page.

→ Learn more about our Adipose-Derived Stem Cell Therapy

Conclusion

Japan’s regulatory framework for regenerative medicine, particularly the Act on the Safety of Regenerative Medicine, offers a structured and safety-conscious environment for patients. It provides a level of oversight that is crucial for such advanced medical technologies. However, the decision to pursue stem cell therapy is a significant one that requires careful research and, most importantly, a detailed consultation with a qualified physician. By understanding the legal landscape and your own health needs, you can make a well-informed choice about your care.

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›